| 產(chǎn)品編號 | bs-4055R-FITC |
| 英文名稱 | Rabbit Anti-phospho-PPAR alpha (Ser12)/FITC Conjugated antibody |
| 中文名稱 | FITC標(biāo)記的磷酸化α型-過氧化酶活化增生受體抗體 |
| 別 名 | PPAR alpha (phospho-Ser12); PPAR alpha (phospho-S12); p-PPAR alpha (Ser12); p-PPAR alpha (S12); hPPAR; MGC2237; MGC2452; NR1C1; Nuclear receptor subfamily 1 group C member 1; Peroxisome Proliferator Activated Receptor alpha; PPAR; PPAR alpha; PPARA; OTTHUMP00000197740; OTTHUMP00000197741; Peroxisome proliferator-activated receptor alpha; PPAR-alpha; PPARA_HUMAN; PPARalpha. |
 |
Journal
PMID
IF
Application
[IF=8.694] Claudia A. Hana. et al. Serum metabolomics analysis reveals increased lipid catabolism in mildly hyperbilirubinemic Gilbert's syndrome individuals. Metabolism. 2021 Dec;125:154913 FC ; Human.
[IF=5.23] M?lzer, Christine, et al. "Features of an altered AMPK metabolic pathway in Gilbert’s Syndrome, and its role in metabolic health." Scientific Reports 6 (2016): 30051. FCM ; Human.
|
| 規(guī)格價格 | 100ul/2980元 購買 大包裝/詢價 |
| 說 明 書 | 100ul |
| 產(chǎn)品類型 | 磷酸化抗體 |
| 研究領(lǐng)域 | 腫瘤 細(xì)胞生物 免疫學(xué) 轉(zhuǎn)錄調(diào)節(jié)因子 激酶和磷酸酶 |
| 抗體來源 | Rabbit |
| 克隆類型 | Polyclonal |
| 交叉反應(yīng) | Human, Mouse, Rat, (predicted: Dog, Pig, Cow, Horse, Guinea Pig, ) |
| 產(chǎn)品應(yīng)用 | IF=1:50-200
not yet tested in other applications. optimal dilutions/concentrations should be determined by the end user. |
| 分 子 量 | 52kDa |
| 性 狀 | Lyophilized or Liquid |
| 濃 度 | 1mg/ml |
| 免 疫 原 | KLH conjugated Synthesised phosphopeptide derived from human PPAR alpha around the phosphorylation site of ser12 |
| 亞 型 | IgG |
| 純化方法 | affinity purified by Protein A |
| 儲 存 液 | 0.01M TBS(pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol. |
| 保存條件 | Store at -20 °C for one year. Avoid repeated freeze/thaw cycles. The lyophilized antibody is stable at room temperature for at least one month and for greater than a year when kept at -20°C. When reconstituted in sterile pH 7.4 0.01M PBS or diluent of antibody the antibody is stable for at least two weeks at 2-4 °C. |
| 產(chǎn)品介紹 |
background: Peroxisome proliferators are nongenotoxic carcinogens which are purported to exert their effect on cells through their interaction with members of the nuclear hormone receptor family, termed Peroxisome Proliferator Activated Receptors (PPARs). Nuclear hormone receptors are ligand dependent intracellular proteins that stimulate transcription of specific genes by binding to specific DNA sequences following activation by the appropriate ligand. Studies indicate that PPARs are activated by peroxisome proliferators such as clofibric acid, nafenopin, and WY-14,643, as well as by some fatty acids. It has also been shown that PPARs can induce transcription of acyl coenzyme A oxidase and cytochrome P450 A6 (CYP450 A6) through interaction with specific response elements. PPAR alpha is activated by free fatty acids including linoleic, arachidonic, and oleic acids. Induction of peroxisomes by this mechanism leads to a reduction in blood triglyceride levels. PPAR alpha is expressed mainly in skeletal muscle, heart, liver, and kidney and is thought to regulate many genes involved in the beta-oxidation of fatty acids. Activation of rat liver PPAR alpha has been shown to suppress hepatocyte apoptosis. PPAR alpha, like several other nuclear hormone receptors, heterodimerizes with retinoic X receptor (RXR) alpha to form a transcriptionally competent complex. Function: Ligand-activated transcription factor. Key regulator of lipid metabolism. Activated by the endogenous ligand 1-palmitoyl-2-oleoyl-sn-glycerol-3-phosphocholine (16:0/18:1-GPC). Activated by oleylethanolamide, a naturally occurring lipid that regulates satiety (By similarity). Receptor for peroxisome proliferators such as hypolipidemic drugs and fatty acids. Regulates the peroxisomal beta-oxidation pathway of fatty acids. Functions as transcription activator for the ACOX1 and P450 genes. Transactivation activity requires heterodimerization with RXRA and is antagonized by NR2C2. Subunit: Heterodimer; with RXRA. This heterodimerization is required for DNA binding and transactivation activity. Interacts with AKAP13, LPIN1 and PRDM16. Also interacts with PPARBP coactivator in vitro. Interacts with CITED2; the interaction stimulates its transcriptional activity (By similarity). Interacts with NCOA3 and NCOA6 coactivators. Interacts with ASXL1 AND ASXL2. Subcellular Location: Nucleus. Tissue Specificity: Skeletal muscle, liver, heart and kidney. Similarity: Belongs to the nuclear hormone receptor family. NR1 subfamily. Contains 1 nuclear receptor DNA-binding domain. Database links: Entrez Gene: 5465 Human Entrez Gene: 19013 Mouse Omim: 170998 Human SwissProt: Q07869 Human SwissProt: Q6I9S0 Human SwissProt: P23204 Mouse SwissProt: Q542P9 Mouse Unigene: 103110 Human Unigene: 710044 Human Unigene: 212789 Mouse Unigene: 9753 Rat Important Note: This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications. |
